Biotechnology

GeoVax Labs

GeoVax Labs released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.6203 (forecast USD -0.845)

GeoVax Labs released FY2025 Annual Earnings on April 15 (EST), actual revenue USD 2.489 M (forecast USD 1.747 M), actual EPS USD -22.3954 (forecast USD -24.7625)

GeoVax Labs released FY2025 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.5474 (forecast USD -5.3475)

Roth MKM Analyst Maintains Buy Rating on GeoVax Labs, Price Target at $14.00

GeoVax Labs released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -1.1092

GeoVax Labs released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -7.7868 (forecast USD -6.625)

GeoVax Labs to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 0, EPS USD -0.265

Aschoff Provides Healthcare Industry Stock Analysis and Recommendations

GeoVax Labs released FY2025 Q2 earnings on July 28 After-Market EST, actual revenue USD 852.28 K (forecast USD 533.33 K), actual EPS USD -8.7403 (forecast USD -9)

GeoVax Labs released FY2025 Semi-Annual earnings on July 28 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -0.7889

GeoVax Labs to Release FY2025 Q2 Earnings on July 28 After-Market EST, Forecast Revenue USD 533.33K, EPS USD -0.36

GeoVax Labs Conducts Public Offering of Approximately 9.2 Million Units

GeoVax Labs Announces Patent for Malaria Vaccine

GeoVax Responds to WHO Declaring Monkeypox a Global Health Emergency

GeoVax to present positive immune data of GEO-CM04S1 in CLL patients at EHA

GeoVax Highlights Broad Cross-Protective Immunity of Its Multi-Antigen COVID-19 Vaccine Candidate

D. Boral Capital Downgrades Geovax Labs' Price Target and Rating

GeoVax Terminates BARDA Contract and Reports Q1 Earnings

GeoVax Labs released FY2025 Q1 earnings on May 1 After-Market EST, actual revenue USD 1.637 M (forecast USD 1.25 M), actual EPS USD -11.2039 (forecast USD -16.4375)

GeoVax Labs to release FY2025 Q1 earnings on May 1 After-Market EST, forecast revenue USD 1.25 M, EPS USD -0.6575

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

GOVX

IBBQ

SBIO

LABU

GeoVax Labs, Inc. emphasizes the critical need for scalable domestic vaccine manufacturing and diversified supply capabilities in light of escalating global infectious disease threats, including the Ebola outbreak and mpox developments. CEO David A. Dodd highlighted the importance of their GEO-MVA vaccine candidate, which is advancing towards a Phase 3 trial. The company aims to enhance biodefense preparedness and has received positive feedback from the European Medicines Agency for its regulatory pathway.

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats

GOSS

LTRN

In Monday's pre-market session, Sunshine Biopharma surged 635.6% to $2.09, while Geovax Labs rose 169.91% to $3.32. Other gainers included Virax Biolabs (+100.71%), AIM ImmunoTech (+45.73%), and Quantum Cyber (+17.05%). Conversely, WORK Medical Tech fell 25.5%, P3 Health Partners dropped 22.53%, and Artelo Biosciences decreased by 17.4%. Citius Pharmaceuticals, Gossamer Bio, and Lantern Pharma also saw declines following their Q1 earnings reports.

benzinga_article

Gossamer Bio

Lantern Pharma

P3 Health Partners

Citius Pharma

Artelo Biosciences

VG Health

Quantum Cyber NV

Picard Medical

WORK Medical Tech

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

Mainz Biomed NV

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Watch

GeoVax Labs | 8-K: FY2026 Q1 Revenue: USD 0

GOVXW

GeoVax reported a Q1 2026 net loss of $5.3 million, with cash reserves of $1.3 million. Revenue from government contracts was $0, down from $1.6 million in Q1 2025 due to a contract termination. The company is advancing its GEO-MVA vaccine program and Gedeptin strategies in immuno-oncology. R&D expenses decreased to $3.9 million, while general and administrative expenses fell to $1.4 million. The company plans to initiate a Phase 3 trial for GEO-MVA and continues to focus on Gedeptin's development.

TradingView

Invesco Biotechnology & Genome ETF

GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans

GeoVax Labs | 8-K: FY2025 Revenue: USD 2.489 M

GeoVax Labs reported $2.489 million in revenue for the year, with a net loss of $(21.465) million, an improvement from the previous year. The operating loss was $(21.639) million, attributed to reduced R&D spending. The company is advancing its GEO-MVA program toward Phase 3 and has multiple Phase 2 trials for GEO-CM04S1. The Gedeptin cancer program has completed Phase 1/2 trials. GeoVax has raised capital through equity tranches to support its initiatives, with a cash runway extending into mid-Q2 2026.

GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M

GeoVax Labs | 10-K: FY2025 Revenue: USD 2.489 M

ARKG

In Wednesday's after-market session, Staar Surgical (NASDAQ:STAA) led the gainers with a 19.7% increase to $25.0, followed by Healthcare Triangle (NASDAQ:HCTI) up 15.57% to $2.82. Other gainers included AVITA Medical (NASDAQ:RCEL) +12.19%, Talphera (NASDAQ:TLPH) +8.86%, Geovax Labs (NASDAQ:GOVX) +8.44%, and Modular Medical (NASDAQ:MODD) +7.84%. On the downside, Scienture Holdings (NASDAQ:SCNX) fell 8.2% to $0.32, with Zhengye Biotechnology (NASDAQ:ZYBT) down 8.12%. Other losers included RxSight (NASDAQ:RXST), Profusa (NASDAQ:PFSA), Impact BioMedical (AMEX:IBO), and Axe Compute (NASDAQ:AGPU).

Ark Genomic Revolution ETF

STAAR Surgical

Avita Medical

Profusa

RxSight

Modular Medical

iShares US Medical Devices

Talphera

SPDR S&P Health Equip

Health Care Select Sector SPDR

12 Health Care Stocks Moving In Wednesday's After-Market Session

GeoVax Labs has raised approximately $863,000 through a warrant exercise inducement, allowing existing warrant holders to exercise 634,658 warrants at a reduced price of $1.36 per share. In return, the company will issue new warrants for up to 1,269,316 shares at the same price, valid for five years pending Nasdaq approval. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction, receiving a 7% fee and up to $40,000 in legal expenses.

GeoVax Labs Raises $863K Via Warrant Exercise Inducement; Issues New 5-Year Warrants at $1.36

GeoVax Labs(GOVX.US)